New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph
admin 5th September 2017 Uncategorised 0Novartis’ drug-development chief, Vas Narasimhan, will take over as CEO in February 2018 from Joe Jimenez, who is retiring. Narasimhan will enjoy the fruits of Novartis’ groundbreaking FDA approval of the first CAR-T treatment for cancer, but he will also be inheriting several challenges, not the least of which is pricing pressure on both branded and generic drugs.
More: New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph
Source: fierce